-
MANNIN RESEARCH TO PRESENT GLAUCOMA THERAPEUTICS TREATMENT AT MEDCITY INVEST APRIL 12 -13 2016
Mannin Research is pleased to announce that it will present at MATTER Midwest University HealthTech Showcase on April 12 – 13th, 2016. Mannin Research will present and discuss its glaucoma treatment technology at the forum to an audience of sophisticated healthcare investors. The showcase is part of the opening reception for the MedCity INVEST conference. MedCity INVEST(formerly the MidAmerica Healthcare Venture Forum) a national healthcare investing conference based in... -
MANNIN RESEARCH INC. IS ACCEPTED TO THE CHICAGO-CANADA MENTORSHIP PROGRAM (C2MP)
Mannin Research Inc. is proud to announce that it has been selected as one of three companies to participate in the C2MP program. The C2MP program is a tailor-made mentioning program focused on life science innovators. In partnership with the Chicago Innovation Mentors (CIM@MATTER) organization, the Canadian Trade Commissioner Service will catalyze and accelerate technology commercialization opportunities in the Chicago area by matching experienced and supportive mentoring teams with... -
Q BIOMED INC. AND MANNIN RESEARCH INC. SIGN DEFINITIVE LICENSE AGREEMENT
Platform technology well positioned to be a First-In-Class molecule for the treatment of glaucoma as well as cystic kidney disease and others. NEW YORK, October 30, 2015 Q BioMed Inc. (OTC Pink: QBIO), a biotechnology acceleration company is pleased to announce it has signed a definitive license, with the option to acquire, the platform technology assets of Mannin Research Inc. Mannin Research Inc., is a biotechnology company leading the development...
